These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
11. Outcome measures for trials of remyelinating agents in multiple sclerosis: retrospective longitudinal analysis of visual evoked potential latency. Niklas A, Sebraoui H, Hess E, Wagner A, Then Bergh F. Mult Scler; 2009 Jan; 15(1):68-74. PubMed ID: 18701569 [Abstract] [Full Text] [Related]
12. [Visual evoked potentials in multiple sclerosis]. Paty J, Brenot P, Henry P, Faure JM. Rev Neurol (Paris); 1976 Sep; 132(9):605-21. PubMed ID: 996388 [Abstract] [Full Text] [Related]
13. Progression of visual evoked potential abnormalities in multiple sclerosis and optic neuritis. Alshuaib WB. Electromyogr Clin Neurophysiol; 2000 Jun; 40(4):243-52. PubMed ID: 10907603 [Abstract] [Full Text] [Related]
14. Electrophysiological evidence for heterogeneity of lesions in optic neuritis. Klistorner A, Graham S, Fraser C, Garrick R, Nguyen T, Paine M, O'Day J, Grigg J, Arvind H, Billson FA. Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4549-56. PubMed ID: 17898277 [Abstract] [Full Text] [Related]
16. A double-blind, randomized trial of IV immunoglobulin treatment in acute optic neuritis. Roed HG, Langkilde A, Sellebjerg F, Lauritzen M, Bang P, Mørup A, Frederiksen JL. Neurology; 2005 Mar 08; 64(5):804-10. PubMed ID: 15753413 [Abstract] [Full Text] [Related]